These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8551986)

  • 1. On the correction for radioactive decay in pharmacokinetic modeling.
    Williams LE; Odom-Maryon TL; Liu A; Chai A; Raubitschek AA; Wong JY; D'Argenio DZ
    Med Phys; 1995 Oct; 22(10):1619-26. PubMed ID: 8551986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.
    Stevens MW; Henry RL; Owens SM; Schutz R; Gentry WB
    MAbs; 2014; 6(6):1649-56. PubMed ID: 25484042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans.
    Ohnuma T; Norton L; Andrejczuk A; Holland JF
    Cancer Res; 1985 Jan; 45(1):464-9. PubMed ID: 3965152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency.
    Aston PJ; Derks G; Raji A; Agoram BM; van der Graaf PH
    J Theor Biol; 2011 Jul; 281(1):113-21. PubMed ID: 21557949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic modeling.
    Strand SE; Zanzonico P; Johnson TK
    Med Phys; 1993; 20(2 Pt 2):515-27. PubMed ID: 8492760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parametric images of antibody pharmacokinetics based on serial quantitative whole-body imaging and blood sampling.
    Gleisner KS; Nickel M; Lindén O; Erlandsson K; Wingårdh K; Strand SE
    J Nucl Med; 2007 Aug; 48(8):1369-78. PubMed ID: 17673426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of specific activity of labeled ligands by nonlinear regression analysis.
    Durr JA
    Am J Physiol; 1993 Nov; 265(5 Pt 1):E728-35. PubMed ID: 8238499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of radioactive decay in pharmacokinetic modeling: influence on parameter estimation in cardiac 13N-PET.
    Glatting G; Reske SN
    Med Phys; 1999 Apr; 26(4):616-21. PubMed ID: 10227364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the immunoreactivity of radiolabeled monoclonal antibodies: a theoretical analysis.
    Glatting G; Reske SN
    Cancer Biother Radiopharm; 2006 Feb; 21(1):15-21. PubMed ID: 16480327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model.
    Baxter LT; Zhu H; Mackensen DG; Butler WF; Jain RK
    Cancer Res; 1995 Oct; 55(20):4611-22. PubMed ID: 7553638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases.
    Lv Y; Cheung NK; Fu BM
    J Nucl Med; 2009 Aug; 50(8):1324-31. PubMed ID: 19617331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans.
    Eger RR; Covell DG; Carrasquillo JA; Abrams PG; Foon KA; Reynolds JC; Schroff RW; Morgan AC; Larson SM; Weinstein JN
    Cancer Res; 1987 Jun; 47(12):3328-36. PubMed ID: 3581071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADVAN-style analytical solutions for common pharmacokinetic models.
    Abuhelwa AY; Foster DJ; Upton RN
    J Pharmacol Toxicol Methods; 2015; 73():42-8. PubMed ID: 25841670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.
    Baxter LT; Zhu H; Mackensen DG; Jain RK
    Cancer Res; 1994 Mar; 54(6):1517-28. PubMed ID: 8137258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the physical decay correction of the (18)F-FDG input function in dynamic PET imaging justified?
    Laffon E; Barret O; Marthan R; Ducassou D
    J Nucl Med Technol; 2009 Jun; 37(2):111-3. PubMed ID: 19447853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Explicit reformulations of the Lambert W-omega function for calculations of the solutions to one-compartment pharmacokinetic models with Michaelis-Menten elimination kinetics.
    Goličnik M
    Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):121-7. PubMed ID: 21533844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
    Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
    Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The connection between the steady state (Vss) and terminal (Vbeta) volumes of distribution in linear pharmacokinetics and the general proof that Vbeta >/= Vss.
    Berezhkovskiy LM
    J Pharm Sci; 2007 Jun; 96(6):1638-52. PubMed ID: 17117429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronopharmacokinetics of ethanol. I. Review of the literature and theoretical considerations.
    Sturtevant FM
    Chronobiologia; 1976; 3(3):237-62. PubMed ID: 797559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.